Novocure Ltd
NVCR | NASDAQ
$16.53
-$0.16 (-0.96%)
At close: Sep 21, 2026, 4:00 PM ET
$17.38
+$0.85 (+5.14%)
Pre-market:
Sep 22, 2026, 9:09 AM ET
Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Frank Leonard | Chief Executive Officer & Director |
| Christoph Brackmann | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Adam Daney | Head of Investor Relations |
| Barak Ben Arye | General Counsel |
| Michael Puri | Chief Human Resources Officer |
| Uri Weinberg | Chief Innovation Officer & Chief Medical Officer |
| William F. Doyle | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 8-K | Current Report |
| Jul 23, 2026 | 8-K | Current Report |
| Jul 23, 2026 | 10-Q | Quarterly Report |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jun 30, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 05, 2026 | 8-K | Current Report |
Novocure Ltd
| Country | Switzerland |
| IPO Date | Oct 1, 2015 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 1,605 |
| CEO | Frank Leonard |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| SIC Code | 3841 |
Recent News
- 4 days ago / marketbeat.comNovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
- 8 days ago / seekingalpha.comNovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 15 days ago / zacks.comNovocure Reports Patient Data Exposure in Cybersecurity Incident
- 20 days ago / businesswire.comNovocure Announces Upcoming Investor Events
- 21 days ago / reuters.comOncology firm Novocure says cyberattack exposed US patient records
- 25 days ago / zacks.comWall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
- 1 month ago / zacks.comAre You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
- 1 month ago / zacks.comWall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
- 2 months ago / zacks.comNovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
- 2 months ago / zacks.comWall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
Add to Watchlist
Select watchlists to add or remove NVCR